Olanzapine versus haloperidol in schizoaffective disorder, bipolar type

Mauricio Tohen, Fan Zhang, Paul E. Keck, Peter D. Feldman, Richard C. Risser, Pierre V. Tran, Alan Breier

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: The present analysis was performed on data from a subsample of patients with schizoaffective disorder, bipolar type, who participated in a multicenter, double-blind study comparing olanzapine to haloperidol. Methods: Patients with schizoaffective disorder bipolar type, characterized as currently manic, mixed, depressed, or euthymic, were assessed weekly for 6 weeks during treatment with either olanzapine or haloperidol. Manic symptoms were measured using the sum of six items of the BPRS, and depressive symptoms were assessed using the Montgomery-Asberg Depression Rating Scale. In addition, cognitive functioning was measured using the sum of seven items from the PANSS. Repeated measures analyses were performed using random coefficients regression of the serial measurement of manic, cognitive, and depressive symptoms. Results: A significant treatment difference was detected overall, indicating that olanzapine was significantly more effective than haloperidol in reducing symptoms of depression and improving patients' cognitive symptoms. The superiority of olanzapine over haloperidol in the reduction of manic symptoms did not reach statistical significance (P = .052). The greatest improvement in both manic and cognitive symptoms was seen in the olanzapine-treated 'currently manic' subgroup, and least improvement in the haloperidol-treated 'euthymic' subgroup. Depressive symptoms were most improved in the olanzapine-treated 'depressed' subgroup, and least improved in the corresponding haloperidol subgroup. Conclusions: Overall, olanzapine was superior to haloperidol with respect to thymoleptic effects in patients with schizoaffective disorder, bipolar type.

Original languageEnglish (US)
Pages (from-to)133-140
Number of pages8
JournalJournal of Affective Disorders
Volume67
Issue number1-3
DOIs
StatePublished - 2001

Fingerprint

olanzapine
Haloperidol
Psychotic Disorders
Neurobehavioral Manifestations
Depression
Double-Blind Method
Antidepressive Agents

Keywords

  • Atypical antipsychotic
  • Bipolar disorder
  • Haloperidol
  • Mania
  • Olanzapine
  • Schizoaffective disorder

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

Tohen, M., Zhang, F., Keck, P. E., Feldman, P. D., Risser, R. C., Tran, P. V., & Breier, A. (2001). Olanzapine versus haloperidol in schizoaffective disorder, bipolar type. Journal of Affective Disorders, 67(1-3), 133-140. https://doi.org/10.1016/S0165-0327(00)00303-7

Olanzapine versus haloperidol in schizoaffective disorder, bipolar type. / Tohen, Mauricio; Zhang, Fan; Keck, Paul E.; Feldman, Peter D.; Risser, Richard C.; Tran, Pierre V.; Breier, Alan.

In: Journal of Affective Disorders, Vol. 67, No. 1-3, 2001, p. 133-140.

Research output: Contribution to journalArticle

Tohen, M, Zhang, F, Keck, PE, Feldman, PD, Risser, RC, Tran, PV & Breier, A 2001, 'Olanzapine versus haloperidol in schizoaffective disorder, bipolar type', Journal of Affective Disorders, vol. 67, no. 1-3, pp. 133-140. https://doi.org/10.1016/S0165-0327(00)00303-7
Tohen, Mauricio ; Zhang, Fan ; Keck, Paul E. ; Feldman, Peter D. ; Risser, Richard C. ; Tran, Pierre V. ; Breier, Alan. / Olanzapine versus haloperidol in schizoaffective disorder, bipolar type. In: Journal of Affective Disorders. 2001 ; Vol. 67, No. 1-3. pp. 133-140.
@article{c3713fbd74584db9ad9c80bc3e22f984,
title = "Olanzapine versus haloperidol in schizoaffective disorder, bipolar type",
abstract = "Background: The present analysis was performed on data from a subsample of patients with schizoaffective disorder, bipolar type, who participated in a multicenter, double-blind study comparing olanzapine to haloperidol. Methods: Patients with schizoaffective disorder bipolar type, characterized as currently manic, mixed, depressed, or euthymic, were assessed weekly for 6 weeks during treatment with either olanzapine or haloperidol. Manic symptoms were measured using the sum of six items of the BPRS, and depressive symptoms were assessed using the Montgomery-Asberg Depression Rating Scale. In addition, cognitive functioning was measured using the sum of seven items from the PANSS. Repeated measures analyses were performed using random coefficients regression of the serial measurement of manic, cognitive, and depressive symptoms. Results: A significant treatment difference was detected overall, indicating that olanzapine was significantly more effective than haloperidol in reducing symptoms of depression and improving patients' cognitive symptoms. The superiority of olanzapine over haloperidol in the reduction of manic symptoms did not reach statistical significance (P = .052). The greatest improvement in both manic and cognitive symptoms was seen in the olanzapine-treated 'currently manic' subgroup, and least improvement in the haloperidol-treated 'euthymic' subgroup. Depressive symptoms were most improved in the olanzapine-treated 'depressed' subgroup, and least improved in the corresponding haloperidol subgroup. Conclusions: Overall, olanzapine was superior to haloperidol with respect to thymoleptic effects in patients with schizoaffective disorder, bipolar type.",
keywords = "Atypical antipsychotic, Bipolar disorder, Haloperidol, Mania, Olanzapine, Schizoaffective disorder",
author = "Mauricio Tohen and Fan Zhang and Keck, {Paul E.} and Feldman, {Peter D.} and Risser, {Richard C.} and Tran, {Pierre V.} and Alan Breier",
year = "2001",
doi = "10.1016/S0165-0327(00)00303-7",
language = "English (US)",
volume = "67",
pages = "133--140",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Olanzapine versus haloperidol in schizoaffective disorder, bipolar type

AU - Tohen, Mauricio

AU - Zhang, Fan

AU - Keck, Paul E.

AU - Feldman, Peter D.

AU - Risser, Richard C.

AU - Tran, Pierre V.

AU - Breier, Alan

PY - 2001

Y1 - 2001

N2 - Background: The present analysis was performed on data from a subsample of patients with schizoaffective disorder, bipolar type, who participated in a multicenter, double-blind study comparing olanzapine to haloperidol. Methods: Patients with schizoaffective disorder bipolar type, characterized as currently manic, mixed, depressed, or euthymic, were assessed weekly for 6 weeks during treatment with either olanzapine or haloperidol. Manic symptoms were measured using the sum of six items of the BPRS, and depressive symptoms were assessed using the Montgomery-Asberg Depression Rating Scale. In addition, cognitive functioning was measured using the sum of seven items from the PANSS. Repeated measures analyses were performed using random coefficients regression of the serial measurement of manic, cognitive, and depressive symptoms. Results: A significant treatment difference was detected overall, indicating that olanzapine was significantly more effective than haloperidol in reducing symptoms of depression and improving patients' cognitive symptoms. The superiority of olanzapine over haloperidol in the reduction of manic symptoms did not reach statistical significance (P = .052). The greatest improvement in both manic and cognitive symptoms was seen in the olanzapine-treated 'currently manic' subgroup, and least improvement in the haloperidol-treated 'euthymic' subgroup. Depressive symptoms were most improved in the olanzapine-treated 'depressed' subgroup, and least improved in the corresponding haloperidol subgroup. Conclusions: Overall, olanzapine was superior to haloperidol with respect to thymoleptic effects in patients with schizoaffective disorder, bipolar type.

AB - Background: The present analysis was performed on data from a subsample of patients with schizoaffective disorder, bipolar type, who participated in a multicenter, double-blind study comparing olanzapine to haloperidol. Methods: Patients with schizoaffective disorder bipolar type, characterized as currently manic, mixed, depressed, or euthymic, were assessed weekly for 6 weeks during treatment with either olanzapine or haloperidol. Manic symptoms were measured using the sum of six items of the BPRS, and depressive symptoms were assessed using the Montgomery-Asberg Depression Rating Scale. In addition, cognitive functioning was measured using the sum of seven items from the PANSS. Repeated measures analyses were performed using random coefficients regression of the serial measurement of manic, cognitive, and depressive symptoms. Results: A significant treatment difference was detected overall, indicating that olanzapine was significantly more effective than haloperidol in reducing symptoms of depression and improving patients' cognitive symptoms. The superiority of olanzapine over haloperidol in the reduction of manic symptoms did not reach statistical significance (P = .052). The greatest improvement in both manic and cognitive symptoms was seen in the olanzapine-treated 'currently manic' subgroup, and least improvement in the haloperidol-treated 'euthymic' subgroup. Depressive symptoms were most improved in the olanzapine-treated 'depressed' subgroup, and least improved in the corresponding haloperidol subgroup. Conclusions: Overall, olanzapine was superior to haloperidol with respect to thymoleptic effects in patients with schizoaffective disorder, bipolar type.

KW - Atypical antipsychotic

KW - Bipolar disorder

KW - Haloperidol

KW - Mania

KW - Olanzapine

KW - Schizoaffective disorder

UR - http://www.scopus.com/inward/record.url?scp=0035721662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035721662&partnerID=8YFLogxK

U2 - 10.1016/S0165-0327(00)00303-7

DO - 10.1016/S0165-0327(00)00303-7

M3 - Article

C2 - 11869760

AN - SCOPUS:0035721662

VL - 67

SP - 133

EP - 140

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 1-3

ER -